Cabotegravir-d₅  (Synonyms: GSK-1265744-d₅; S/GSK1265744-d₅)

Cabotegravir-d₅ is deuterium labeled Cabotegravir.

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

410.38

C₁₉H₁₂D₅F₂N₃O₅

2750534-77-9

1051375-10-0

Solid

White to off-white

FC1=C(CNC(C2=CN3C(C(N([C@@H](C([2H])([2H])[2H])C([2H])([2H])O4)[C@@]4([H])C3)=O)=C(O)C2=O)=O)C=CC(F)=C1

Room temperature in continental US; may vary elsewhere.

• [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]

  [2]. Reese MJ, Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.  [Content Brief]

  [3]. Reese MJ, et al. Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. Xenobiotica. 2015 Sep 4:1-12.  [Content Brief]

  [4]. Bowers GD, Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2015 Jul 1:1-16.  [Content Brief]